High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.

[1]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[2]  G. Kraft,et al.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. , 2003, Blood.

[3]  D. Flockhart,et al.  Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[4]  N. Hellings,et al.  Insights into the immunopathogenesis of multiple sclerosis , 2002, Immunologic research.

[5]  W. Collard,et al.  Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[6]  O. Khan,et al.  Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy , 2001, Multiple sclerosis.

[7]  M. Gobbini,et al.  Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis , 1999, Journal of Neuroimmunology.

[8]  F. Appelbaum,et al.  Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.

[9]  M. Eichelbaum,et al.  Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Appelbaum,et al.  Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Degos,et al.  Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. , 1995, European neurology.

[12]  R. Beck,et al.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.

[13]  R. Herndon,et al.  Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis , 1993, Neurology.

[14]  M. Moore,et al.  Rapid development of enhanced clearance after high‐dose cyclophosphamide , 1988, Clinical pharmacology and therapeutics.

[15]  J. Kovach,et al.  Pharmacokinetics of anticancer agents in humans , 1983 .